SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending amid speculation around potential connections to Elon Musk's Grok AI. The community is also excited about the project's fundamentals, including its zero-tax setup, and a potential listing on Binance. Many participants are expressing bullish sentiment, using terms like "WAGMI" and "To The Moon".

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community celebrates its joke-inspired roots and long-term presence on the Solana blockchain. Many are drawn to its dedicated community, locked liquidity, and association with the popular "What's UpDog?" meme, while others highlight its potential within the broader meme coin landscape.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending amidst community enthusiasm, fueled by its meme-centric nature and comparisons to other successful meme coins. Community members are actively encouraging each other to 'RAGE HARDER' and expressing strong bullish sentiment, while also highlighting growing community and potential for significant gains. The coin is also getting attention from influencers.

Pump.fun

PUMP.X is trending as community members discuss its potential within the Solana ecosystem, particularly alongside tokens like WAGMI. Bullish sentiment seems to be fueled by the platform's mechanics around token buybacks and creator rewards. Some traders are closely watching key support and resistance levels, anticipating potential breakouts.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending as the community rallies around $UPDOG, a Solana-based meme coin exclusively listed on Jupiter's strict list, driving discussions about loading up on the token. The focus is on swapping $SOL for $UPDOG on Jupiter, with community members highlighting the project's long-term development and strong community vibes. Amidst the broader meme coin season, UpDog's unique listing on Jupiter is a key catalyst.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as traders discuss its bullish technical setup and potential for an upside breakout, fueled by recent news of the acquisition of anti-coagulant assets. The community highlights the momentum and strong buyer confidence, while also noting the healthcare technology niche and upcoming milestones for their drug Tecarfarin. Some are watching for volume to confirm the move, and analysts are noting high price targets for the stock.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending due to topline results from its Phase 2b study, with community members eagerly awaiting further details. Some speculate on the potential for significant gains depending on the results, especially related to viral load reduction. The company's work on zelicapavir, an oral RSV N-protein inhibitor, is also drawing attention, particularly its potential in the adult RSV therapeutics market.

Codatta

Codatta ($XNY.X) is trending amid discussions about its on-chain fingerprint verification launch and potential applications of its AI/data utility. The community is analyzing its chart patterns, with some pointing to bullish setups and expecting new highs, while others are watching key support levels for potential entry points. Sentiment is mixed, with some expressing excitement about its potential and others remaining cautious.

FFFFFFFFFFFFFUUUUUUUUUUUUUUUU

$RAGEGUY.X is trending as the community discusses its recent price action and potential for further gains, with some users reporting significant increases. The conversation highlights community excitement and speculation around potential 'V-shape recovery coding'. Mentions of related tokens like $UPDOG.X and $401JK.X are also contributing to the increased interest.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV.X) is trending as the community discusses its strong chart and potential for another leg up, with some highlighting treasury loop mechanisms like airdrops and buybacks. The community also notes ongoing consolidation and recent upward movement, with some suggesting potential buybacks are underway. Furthermore, the community is discussing the partnership of Synthetix and Derive to build derivatives on ETH L1.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Acadia Healthcare Rockets 12% as Activist Investor Drops the Gauntlet

ACHC jumps 12% as Engine Capital pushes for a bold shake-up. Can a board revamp and smarter capital moves revive the battered stock?

Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

HCA Healthcare Trades at a Premium: Buy, Hold, or Avoid the Stock?

HCA trades above peers on valuation, backed by strong cash flow and buybacks, but weighed by debt and sector headwinds.

New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Tenet Healthcare Jumps 46% YTD & Trades Cheap: Should You Buy Now?

THC's 46% YTD surge, upgraded outlook, and discounted valuation highlight its strong growth potential.

Here's Why HCA Healthcare (HCA) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why HCA Healthcare (HCA) is a Top Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Pediatrix Medical Refills Its Buyback Prescription With $250M Dose

MD launches a $250M buyback, fueled by stronger cash flow, leaner operations and robust 2025 profit outlook.

Here's Why HCA Healthcare (HCA) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

HCA Healthcare, Inc. is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities. The firm operates general and acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services, and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was founded by Dr. Thomas F. Frist, Jr in 1968 and is headquartered in Nashville, TN.

HCA Healthcare Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$415.00
Prev Close	$414.89
Open	$417.70
Dividend Yield	0.88%
50-Day Moving Average	$388.95
Beta	0.57
Avg. Volume	1.12M
PE Ratio	17.60

52-Week High	$422.46
52-Week Low	$289.98
Market Capitalization	$98.06B
EPS (Annual)	$22.00
Price to Book	-22.52
Revenue Per Employee	$223,427.21
Enterprise Value/EBITDA	N/A

HCA
HCA Healthcare Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HCA News

HCA HCA Healthcare Inc